Aptevo Therapeutics (NASDAQ:APVO) Raised to Sell at StockNews.com

Aptevo Therapeutics (NASDAQ:APVOGet Free Report) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued on Saturday.

Aptevo Therapeutics Stock Performance

Shares of APVO opened at $2.41 on Friday. Aptevo Therapeutics has a twelve month low of $2.35 and a twelve month high of $207.33. The firm’s fifty day simple moving average is $3.85 and its 200-day simple moving average is $174.10.

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Read More

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.